View Older Stories View More Recent Stories

Aug 12, 2022 04:01PM Clene to Host VISIONARY-MS Results Call and Webcast on August 15
Aug 12, 2022 04:01PM Clene to Host VISIONARY-MS Results Call and Webcast on August 15
Jul 19, 2022 07:05AM Clene (CLNN) Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8
Jul 19, 2022 07:00AM Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8® for the Treatment of ALS
Jul 19, 2022 07:00AM Clene Receives Positive EMA Opinion on Orphan Drug Designation for CNM-Au8® for the Treatment of ALS
Jul 14, 2022 07:02AM Clene (CLNN) Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial
Jul 14, 2022 07:00AM Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial
Jul 14, 2022 07:00AM Clene Reports Significantly Decreased Mortality in RESCUE-ALS Long-Term Open Label Extension Trial
Jun 27, 2022 07:00AM Clene to Participate in Panel Discussion About Innovations in ALS Presented by Maxim Group and Hosted by M-Vest on June 28
Jun 27, 2022 07:00AM Clene to Participate in Panel Discussion About Innovations in ALS Presented by Maxim Group and Hosted by M-Vest on June 28
Jun 2, 2022 07:00AM Clene Salutes Collaboration of ALS Community and Major League Baseball on Lou Gehrig Day
Jun 2, 2022 07:00AM Clene Salutes Collaboration of ALS Community and Major League Baseball on Lou Gehrig Day
Jun 1, 2022 07:00AM New Data from Clene’s RESCUE-ALS Study to be Presented at 2022 ENCALS Meeting
Jun 1, 2022 07:00AM New Data from Clene’s RESCUE-ALS Study to be Presented at 2022 ENCALS Meeting
May 19, 2022 07:32AM Clene (CLNN) Announces $3M Loan from State of Maryland for Development of Commercial Manufacturing Facility
May 19, 2022 07:30AM Clene Receives $3 Million Loan from State of Maryland to Support Development of Commercial Manufacturing Facility
May 19, 2022 07:30AM Clene Receives $3 Million Loan from State of Maryland to Support Development of Commercial Manufacturing Facility
May 16, 2022 08:00AM Clene to Present at Upcoming Investor Conferences
May 16, 2022 08:00AM Clene to Present at Upcoming Investor Conferences
May 9, 2022 08:00AM Clene Reports First Quarter 2022 Financial Results and Recent Operating Highlights
May 9, 2022 08:00AM Clene Reports First Quarter 2022 Financial Results and Recent Operating Highlights
Apr 1, 2022 07:00AM Updated Interim Data from Clene Nanomedicine’s RESCUE-ALS Open-Label Extension Study to be Presented in Emerging Science Program at 2022 AAN Annual Meeting
Apr 1, 2022 07:00AM Updated Interim Data from Clene Nanomedicine’s RESCUE-ALS Open-Label Extension Study to be Presented in Emerging Science Program at 2022 AAN Annual Meeting
Mar 14, 2022 07:02AM Clene (CLNN) Reports Updated Clinical Data from Phase 2 RESCUE-ALS and REPAIR trials and Preclinical ALS data
Mar 14, 2022 07:00AM Clene Nanomedicine Presents Updated Clinical Data from Phase 2 RESCUE-ALS and REPAIR trials and Preclinical ALS data at 2022 MDA Clinical & Scientific Conference
Mar 14, 2022 07:00AM Clene Nanomedicine Presents Updated Clinical Data from Phase 2 RESCUE-ALS and REPAIR trials and Preclinical ALS data at 2022 MDA Clinical & Scientific Conference
Mar 11, 2022 07:05AM Clene (CLNN) Reports FY21 Results, Provides Operating Highlights
Mar 11, 2022 07:00AM Clene Reports Full Year 2021 Financial Results and Recent Operating Highlights
Mar 11, 2022 07:00AM Clene Reports Full Year 2021 Financial Results and Recent Operating Highlights
Mar 3, 2022 07:00AM Clene Nanomedicine to Present at Upcoming Investor Conferences
Mar 3, 2022 07:00AM Clene Nanomedicine to Present at Upcoming Investor Conferences
Feb 24, 2022 07:00AM Clene (CLNN) Reports Data from Two Phase 2 Multiple Sclerosis Trials
Feb 24, 2022 07:00AM Clene Nanomedicine Presents Data from Two Phase 2 Multiple Sclerosis Trials at ACTRIMS Forum 2022
Feb 24, 2022 07:00AM Clene Nanomedicine Presents Data from Two Phase 2 Multiple Sclerosis Trials at ACTRIMS Forum 2022
Feb 18, 2022 07:00AM Clene Nanomedicine to Present Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2022
Feb 18, 2022 07:00AM Clene Nanomedicine to Present Data from Phase 2 Multiple Sclerosis Programs at ACTRIMS Forum 2022
Feb 14, 2022 07:04AM Clene (CLNN) Issues Clinical Program Update
Feb 14, 2022 07:02AM Clene (CLNN) Nanomedicine Provides Clinical Program Update
Feb 14, 2022 07:00AM Clene Nanomedicine Provides Clinical Program Update
Feb 14, 2022 07:00AM Clene Nanomedicine Provides Clinical Program Update
Feb 1, 2022 07:04AM Clene (CLNN) Appoints Morgan Brown as New CFO
Feb 1, 2022 07:00AM Clene Announces New Chief Financial Officer Morgan Brown
Feb 1, 2022 07:00AM Clene Announces New Chief Financial Officer Morgan Brown
Jan 18, 2022 07:00AM Clene Nanomedicine’s Second Asset, CNM-ZnAg, Completes 50% Patient Enrollment in COVID-19 Trial
Jan 18, 2022 07:00AM Clene Nanomedicine’s Second Asset, CNM-ZnAg, Completes 50% Patient Enrollment in COVID-19 Trial
Dec 15, 2021 07:00AM Clene Nanomedicine’s Patent Portfolio Grows to More Than 150 Issued Worldwide, including Two Key Patents Now Validated Across Europe
Dec 13, 2021 07:01AM Clene (CLNN) Announces $1M Grant Award from Maryland Department of Housing and Community Development (DHCD)
Dec 13, 2021 07:00AM Clene Nanomedicine’s Facility Improvement Project Receives $1 Million Grant Award from the Maryland Department of Housing and Community Development (DHCD)
Dec 13, 2021 07:00AM Clene Nanomedicine’s Facility Improvement Project Receives $1 Million Grant Award from the Maryland Department of Housing and Community Development (DHCD)
Dec 10, 2021 07:00AM Clene Nanomedicine to Present RESCUE-ALS Phase 2 Data in Late-Breaking Session at 32nd International Symposium on ALS/MND
View More Recent Stories View Older Stories